EcoDrugPlus

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMPUG00000010222
Gene Symbol: FYN
2 Cross references
261 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMPUG00000017886
Gene Symbol: HCK
2 Cross references
205 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSMPUG00000013488
Gene Symbol: ITK
2 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSMPUG00000000719
Gene Symbol: JAK1
2 Cross references
236 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSMPUG00000004974
Gene Symbol: JAK2
2 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSMPUG00000015797
Gene Symbol: JAK3
4 Cross references
103 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMPUG00000006114
Gene Symbol: KIT
2 Cross references
265 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSMPUG00000010291
Gene Symbol: KRAS
2 Cross references
203 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMPUG00000015261
Gene Symbol: LCK
2 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMPUG00000010464
Gene Symbol: LYN
2 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSMPUG00000016475
Gene Symbol: MALT1
2 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSMPUG00000009973
Gene Symbol: MAPKAPK2
2 Cross references
233 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).